In February 2023, a 5-year-long phase 1 clinical trial of novel adenoviral AAV2-BDNF gene therapy was initiated to test its ability to decrease neuronal loss and promote synaptogenesis in patients with mild cognitive impairment (MCI) and AD [72]. This evidence concerns the gene BDNF and Alzheimer disease.